<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34631915</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.</ArticleTitle><Pagination><MedlinePgn>ofab430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofab430</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">As of March 2021, Japan is facing a fourth wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To prevent further spread of infection, sera cross-neutralizing activity of patients previously infected with conventional SARS-CoV-2 against novel variants is important but has not been firmly established.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">We investigated the neutralizing potency of 81 coronavirus disease 2019 (COVID-19) patients' sera from the first to fourth waves of the pandemic against SARS-CoV-2 D614G, B.1.1.7, P.1, and B.1.351 variants using their authentic viruses.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Most sera had neutralizing activity against all variants, showing similar activity against B.1.1.7 and D614G, but lower activity especially against B.1.351. In the fourth wave, sera-neutralizing activity against B.1.1.7 was significantly higher than that against any other variants, including D614G. The sera-neutralizing activity in less severe patients was lower than that of more severe patients for all variants.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">The cross-neutralizing activity of convalescent sera was effective against all variants but was potentially weaker for B.1.351. The high neutralizing activity specific to B.1.1.7 in the fourth wave suggests that mutations in the virus might cause conformational change of its spike protein, which affects immune recognition of D614G. Our results indicate that individuals who recover from COVID-19 could be protected from the severity caused by infection with newly emerging variants.</AbstractText><CopyrightInformation>Â© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjan</LastName><ForeName>Lidya Handayani</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutandhio</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurahashi</LastName><ForeName>Yukiya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Sachiyo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohma</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Acute Care Medical Center, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Acute Care Medical Center, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arii</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiriu</LastName><ForeName>Tatsunori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Masatsugu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Yasuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">neutralizing activity</Keyword><Keyword MajorTopicYN="N">reinfection</Keyword><Keyword MajorTopicYN="N">variant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34631915</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofab430</ArticleId><ArticleId IdType="pii">ofab430</ArticleId><ArticleId IdType="pmc">PMC8496759</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell. 2021 May 27;184(11):2939-2954.e9</Citation><ArticleIdList><ArticleId IdType="pubmed">33852911</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 Apr;27(4):622-625</Citation><ArticleIdList><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2021 Jan 30;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2021 May 29;397(10289):2049-2059</Citation><ArticleIdList><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 2021 Apr 28;149:e103</Citation><ArticleIdList><ArticleId IdType="pubmed">33908339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2021 Apr 29;184(9):2348-2361.e6</Citation><ArticleIdList><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2021 Apr;20(4):365-373</Citation><ArticleIdList><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2021 Feb 16;72(4):723-724</Citation><ArticleIdList><ArticleId IdType="pubmed">32474577</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2021 May 13;373:n1088</Citation><ArticleIdList><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 May;593(7857):130-135</Citation><ArticleIdList><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 May;593(7857):142-146</Citation><ArticleIdList><ArticleId IdType="pubmed">33780970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Microbe. 2021 Jul;2(7):e283-e284</Citation><ArticleIdList><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Aug;26(8):1200-1204</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2021 Feb;18(2):318-327</Citation><ArticleIdList><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2021 Jan 21;184(2):476-488.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>JMA J. 2021 Jan 29;4(1):41-49</Citation><ArticleIdList><ArticleId IdType="pubmed">33575502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Aug 20;182(4):812-827.e19</Citation><ArticleIdList><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Elife. 2021 Jul 29;10:</Citation><ArticleIdList><ArticleId IdType="pubmed">34323691</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003</Citation><ArticleIdList><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>JMA J. 2021 Jan 29;4(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">33575497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2021 Apr;27(4):620-621</Citation><ArticleIdList><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2021 Mar 9;372:n579</Citation><ArticleIdList><ArticleId IdType="pubmed">33687922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2021 May;593(7858):270-274</Citation><ArticleIdList><ArticleId IdType="pubmed">33723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2021 Aug 10;54(8):1841-1852.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">34246326</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol. 2021 Jan;222:108634</Citation><ArticleIdList><ArticleId IdType="pubmed">33217545</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Feb 18;384(7):610-618</Citation><ArticleIdList><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>